|
Neurobiological Technologies |
|
|
2000 Powell St., Suite 800
Emeryville, CA 94608 USA
phone:510-595-6000
fax:510-595-6006
|
|
| Symbol |
NTII |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.ntii.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Neuroprotective and neuromodulatory agents to treat progressive neurological impairments. |
|
| Management |
| David E. Levy, M.D., Vice President, Clinical Development; Matthew M. Loar, Vice President and Chief Financial Officer; Karl G. Trass, Vice President, Regulatory Affairs & Quality Assurance; Warren W. Wasiewski, M.D. F.A.A.P., Vice President, Chief Medical Officer
|
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Neurobiological Technologies Inc. is an emerging drug development company focused on the clinical development and regulatory approval of neuroscience drugs. |
|
| Products / Services |
The Company develops neuroprotective and neuromodulatory agents to treat progressive neurological impairments characteristic of various nervous system disorders, including diabetic neuropathy and brain cancer.
|
|
|
| Strategy |
The Company's strategy is to in-license and develop early stage drug candidates that target major medical needs and that can be rapidly commercialized. It has two product candidates that have completed or are in Phase III human clinical testing, Memantine and XERECEPT.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
